Garnett and collaborators have screened a panel of several hundred cancer cell lines with 130 drugs under clinical and preclinical investigation,19 and their public data suggest that somatic mutations of CDH1 gene are associated with cellular responses to an androgen receptor antagonist bicalutamide (P = 6.87 × 10−3), categorised in the same class as flutamide (∆CV = −0.271). Here, AR is linked to cancer.